The U.S. Food and Drug Administration approved Eisai and Biogen’s application for IV maintenance dosing of lecanemab on January 27. Previously, the label called for biweekly IV dosing. The new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback